Literature DB >> 26237360

Autologous cytokine-induced killer (CIK) immunotherapy in a case of disseminated tuberculosis.

Xu Ping1, Xu Junchi, Chen Xinnian, Ye Zhijian, Wu Meiying.   

Abstract

A 23-year-old woman had dry cough, fever and chest tightness for 1 months. Through thoracic CT scan and serological examination, the patient was clinically diagnosed as disseminated tuberculosis. she was given anti-tuberculosis therapy combined with autologous cytokine-induced killer (CIK) immunotherapy. Through the close follow-ups we found that after immunotherapy Her condition would have a swift improvement and she do not appear liver damage after a large doses of antibiotic therapy. In conclusion, adjuvant autologous CIK immunotherapy is an effective approach for disseminated tuberculosis.

Entities:  

Mesh:

Year:  2015        PMID: 26237360

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  3 in total

1.  New attempt in tuberculosis treatment: autologous cytokine-induced killer after chemotherapy treatment failure in a case of multi-drug resistant tuberculosis (MTB).

Authors:  Jun-Chi Xu; Xin-Nian Chen; Zhi-Jian Ye; Mei-Ying Wu; Cui-Lin Shi; Pei-Jun Tang; Hui Chen; Xiao-Yan Zhu; Hua-Feng Song; Xu Ping
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 2.  The Research Progress in Immunotherapy of Tuberculosis.

Authors:  Jie Mi; Yan Liang; Jianqin Liang; Wenping Gong; Shuyong Wang; Junxian Zhang; Zhiming Li; Xueqiong Wu
Journal:  Front Cell Infect Microbiol       Date:  2021-11-15       Impact factor: 5.293

3.  Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis.

Authors:  Peijun Tang; Xingnian Chen; Junchi Xu; Yunlong Hu; Zhijian Ye; Xiafang Wang; Yumei Xiao; Xinghua Shen; Jianping Zhang; Yanjun Feng; Cuilin Shi; Xin Yu; Lixian Yi; Xinchun Chen; Binfeng Lu; Ping Xu; Zhongwen Sun; Meiying Wu
Journal:  J Immunol Res       Date:  2022-03-17       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.